Age: 79.0
Sex: M
Vaccine: COVID19
Symptoms: Aphasia, Disease recurrence, Inappropriate schedule of product administration, Magnetic resonance imaging
Clinical narrative: DOSE 1: 04Oct2021; dose 2: 12Jul2022; started losing ability to communicate + complete sentence shortly after the COVID shot of 12Jul2022; started losing ability to communicate + complete sentence shortly after the COVID shot of 12Jul2022; This is a spontaneous report received from a Consumer or other non HCP.  A 79-year-old male patient received BNT162b2 (BNT162B2), on 12Jul2022 as dose 2, single (Lot number: FM0173) at the age of 79 years intramuscular, in left deltoid for covid-19 immunisation. The patient's relevant medical history included: "sometimes have a little hearing disparity among different "deafness"" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: fluzone high-Dose 2012-13 syr (site and route of administration: left upper arm, intramuscular; Lot number: U4490AA), administration date: 16Sep2012, when the patient was 69-year-old, for immunization; fluzone high-Dose 2013-14 syr (site and route of administration: left deltoid, intramuscular; Lot number: U4713AA), administration date: 26Sep2013, when the patient was 70-year-old, for immunization; fluzone high-Dose 2014-15 syr (site and route of administration: left deltoid, intramuscular; Lot number: U4995AA), administration date: 25Aug2014, when the patient was 71-year-old, for immunization; pneumovax 23 syringe (site and route of administration: left deltoid, injection; Lot number: K009105), administration date: 15Sep2014, when the patient was 71-year-old, for immunization; zostavax vial (route of administration: subcutaneous), administration date: 06Oct2009, when the patient was 66-year-old, for immunization; fluzone 2009-10 syringe (route of administration: intramuscular), administration date: 06Oct2009, when the patient was 66-year-old, for immunization; fluzone high-Dose 2010-11 syr (route of administration: intramuscular), administration date: 01Oct2010, when the patient was 67-year-old, for immunization; fluzone high-Dose 2011-2012 syringe (route of administration: intramuscular), administration date: 02Oct2011, when the patient was 68-year-old, for immunization; fluzone high-Dose 2015-16 syr (site and route of administration: left deltoid, intramuscular; Lot number: UI438AA), administration date: 26Sep2015, when the patient was 72-year-old, for immunization; prevnar 13 syringe (site and route of administration: left deltoid, intramuscular; Lot number: M51194), administration date: 16Mar2016, when the patient was 73-year-old, for immunization; fluzone high-Dose 2016-17 syr (site and route of administration: left deltoid, intramuscular; Lot number: UI620AB), administration date: 11Aug2016, when the patient was 73-year-old, for immunization; fluzone high-Dose 2017-18 syr (site and route of administration: left deltoid, intramuscular; Lot number: UI848AB), administration date: 18Sep2017, when the patient was 74-year-old, for immunization; shingrix vial kit (site and route of administration: left deltoid, intramuscular; Lot number: 539A2), administration date: 28Mar2018, when the patient was 75-year-old, for immunization; fluad 2018-2019 syringe (site and route of administration: left deltoid, intramuscular; Lot number: 250788), administration date: 11Sep2018, when the patient was 75-year-old, for immunization; shingrix vial kit (site and route of administration: left deltoid, intramuscular; Lot number: GG2GA), administration date: 22Oct2018, when the patient was 75-year-old, for immunization; boostrix tdap vaccine syringe (site and route of administration: left deltoid, intramuscular; Lot number: 54B74), administration date: 31Oct2018, when the patient was 76-year-old, for immunization; fluad 2019-2020 syringe (site and route of administration: left deltoid, intramuscular; Lot number: 260382), administration date: 07Aug2019, when the patient was 76-year-old, for immunization; fluad quad 2020-2021 syringe (site and route of administration: left deltoid, intramuscular; Lot number: 279794), administration date: 30Aug2020, when the patient was 77-year-old, for immunization; BNT162b2 (DOSE 1, SINGLE, Lot number: FE3592, site and route of administration: left deltoid, intramuscular), administration date: 04Oct2021, when the patient was 78-year-old, for COVID-19 immunization, reaction(s): "About 2-3 weeks later, started having difficulty completing sentence/use/reach word to communicate/complete thought"; fluad quad 2021-2022 syringe (site and route of administration: left deltoid, intramuscular; Lot number: 323503), administration date: 16Oct2021, when the patient was 78-year-old, for immunization; pneumovax 23 syringe (site and route of administration: right deltoid, injection; Lot number: U010533), administration date: 16Oct2021, when the patient was 78-year-old, for immunization. The following information was reported: APHASIA (non-serious), DISEASE RECURRENCE (non-serious) all with onset 2022, outcome "not recovered" and all described as "started losing ability to communicate + complete sentence shortly after the COVID shot of 12Jul2022"; INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 12Jul2022, outcome "unknown", described as "DOSE 1: 04Oct2021; dose 2: 12Jul2022". The event "started losing ability to communicate + complete sentence shortly after the covid shot of 12jul2022" required physician office visit. Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: Although not as constant at the time of the report, the patient still have regular occurrences of losing ability to communicate and complete sentence. The patient had been tested in the hospital in 2023 for early dementia and Alzheimer's and there were no indications of the same.  No follow-up attempts are possible.  Follow-up (12Feb2024): This is a spontaneous follow-up report received from the same Consumer or other non HCP. Updated information includes: updated historical vaccine details, reaction data (new event: started losing ability to communicate + complete sentence shortly after the COVID shot of 12Jul2022), and clinical course details.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300452363 same patient, different doses/events;US-PFIZER INC-202300177736 same patient, different doses/events;